+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the treatment of anemia in patients with chronic kidney disease CKD who are on hemodialysis. This Phase III, investigator-blinded, randomized, multicenter study compares two drugs, efepoetin alfa and darbepoetin alfa, to see how well they maintain hemoglobin levels in these patients. The study aims to maintain hemoglobin between 10.0 gdL and 12.0 gdL, which is important for managing anemia in CKD. Participants will be randomly assigned in a 21 ratio to receive either efepoetin alfa or darbepoetin alfa. Both drugs are given by intravenous injection, typically after dialysis sessions. Efepoetin alfa is administered weekly from Day 1 to Week 28, with possible interval changes to one or two weeks from Week 29 to Week 52 based on investigator judgment. The study consists of three periods screening up to 28 days, treatment about 52 weeks, and a 4-week follow-up with phone contacts up to Week 56 or the last visit. During the study, participants will undergo regular assessments including hemoglobin level monitoring to evaluate the mean change between Week 20 and Week 28. Safety and efficacy are closely observed, with dosages adjusted to maintain target hemoglobin levels. Follow-up will include phone contacts to monitor participants up to Week 56. The total participation duration is approximately one year, starting from screening through treatment and follow-up.

Age: 18Years +All GendersPhase 3
58 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying healthy infants in Indonesia to compare the immune response and safety of two vaccines Minhais 13-valent Pneumococcal Polysaccharide Conjugate Vaccine PCV13-DTTT, also called Pneuminvac and Pfizers 13-valent Pneumococcal Conjugate Vaccine PCV13, known as Prevenar 13. The study focuses on infants aged 6 to 8 weeks and aims to show that Pneuminvac produces immune responses that are not worse than Prevenar 13 after a booster dose, while also monitoring vaccine safety when given together with a hexavalent vaccine. About 500 infants will be randomly assigned to two groups one receiving Pneuminvac and the other receiving Prevenar 13. Both vaccines will be given at 2, 4, and 12 to 15 months of age. Additionally, all infants will receive the hexavalent vaccine at 2, 3, and 4 months of age. This design follows World Health Organization recommendations for infant vaccination schedules. Participants will attend scheduled visits for vaccinations and assessments, including blood tests to measure immune responses one month after the booster dose. Safety will be closely tracked by recording any side effects after each vaccine dose and serious adverse events up to six months after the booster. The study aims to evaluate the percentage of infants with protective antibody levels and compare immune responses between vaccines, with total participation lasting from enrollment until several months after the final vaccine dose.

Age: 6Weeks - 8WeeksAll GendersPhase 3
3 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.

Age: 14Years +All GendersPhase 3
42 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
C

Actively Recruiting

Healthy Volunteer

Skin rejuvenation aims to improve the signs of skin aging, which involve changes in the skins layers including reduced collagen leading to thinner skin, laxity, and wrinkles. This trial evaluates and compares two types of laser therapies, fractional CO laser and long-pulsed 1064-nm NdYAG laser, both used to stimulate collagen production and improve skin condition. The goal is to assess their effects on dermal thickness, skin elasticity, wrinkles, and overall aesthetic improvement in adults aged 30 to 59 with moderate skin aging.

Age: 30Years - 59YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

This research aims to understand how a modified poco-poco exercise affects aging markers and frailty levels in elderly people living in the community. The study focuses on people aged 60 and older in Bandung, Indonesia, investigating changes in global DNA methylation, GDF15 levels, Lamin A COP levels, and the degree of frailty after exercise. Frailty is a common issue in older adults linked to worsening health, and this study explores whether exercise can influence key biological markers related to aging. Participants will engage in a multicomponent exercise program that includes flexibility, balance, aerobic, and muscle-strengthening activities incorporated into a modified poco-poco routine. This exercise will be performed three times a week for 12 weeks. The modified exercise adds muscle strengthening to the traditional poco-poco exercise to better address the needs of frail elderly individuals. Throughout the study, researchers will measure changes in the participants levels of global DNA methylation, GDF15, Lamin A COP, and frailty at the start and after 12 weeks. Participants will be regularly assessed to track these biological and physical changes. The study is sponsored by Universitas Padjadjaran and aims to help improve health strategies for the elderly community through physical activity.

Age: 60Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

This research aims to evaluate the effectiveness of adding External Counterpulsation ECP therapy to standard medical treatment for patients with stable angina pectoris who are waiting for coronary artery bypass grafting CABG surgery. The study addresses the longer waiting times for CABG in Indonesia, which may increase risks during this period. The goal is to assess whether ECP can relieve symptoms and improve heart function and quality of life in these patients. Participants will be randomly assigned to either the intervention group receiving ECP therapy or the control group receiving only medical treatment. ECP therapy involves 36 sessions, each lasting one hour, conducted five days a week with an initial pressure of 300mmHg. The control group will not receive this therapy. The study will compare changes in heart function and symptoms between the two groups. Participants will undergo assessments before and after the seven-week intervention period, including echocardiography, treadmill tests, and questionnaires measuring angina severity and quality of life. Additional tests may include nuclear myocardial perfusion imaging and blood tests for heart-related biomarkers. Researchers will monitor major adverse cardiac events over two years and perform safety oversight. The total study duration includes the seven-week intervention and long-term follow-up for safety and effectiveness.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating whether a new non-sputum-based diagnostic test and other related interventions can increase tuberculosis TB case notifications and improve TB diagnosis in healthcare facilities in Indonesia. This cluster-randomised controlled trial compares a diagnostic intervention package delivered in healthcare facilities and communities with the standard of care. The study is part of a larger project addressing delays and challenges in TB diagnosis, especially in low-resource settings where many patients cannot produce sputum samples needed for traditional tests. The intervention package includes introducing a new near point-of-care nPOC TB test, optimizing clinical algorithms to incorporate this test, promotional activities to increase patient attendance and test use in clinics and pharmacies, and household contact investigations supported by community health volunteers. Healthcare facilities in the intervention arm receive this multi-component package, while those in the control arm continue standard care but receive refresher training on TB case notification. Participants will be involved over a follow-up period of 12 months after the intervention roll-out, with TB case notifications and other outcomes measured from national TB information systems. Additional sub-studies will assess patient pathways, costs, provider testing behavior, and health system diagnostic costs. Outcomes include changes in TB case notifications, diagnostic confirmation rates, time to diagnosis, healthcare visits before diagnosis, and costs related to TB diagnosis in both healthcare and community settings.

Age: 29Days +All GendersPhase Not Applicable
1 location
M

Actively Recruiting

This research aims to understand acute malnutrition in infants younger than 6 months admitted to pediatric or perinatology wards in hospitals across Indonesia. The study will observe how common acute malnutrition is in this age group and investigate the outcomes of nutrition therapy, including recovery, growth improvement, complications, and death. It also seeks to identify factors linked to successful nutrition treatment based on the 2023 WHO criteria. The study is observational and will not provide experimental treatments. Instead, it will collect detailed measurements of infants weight, length, head circumference, and mid-upper arm circumference at baseline, day 3, day 7, and weekly until hospital discharge. Information about birth history, feeding, illnesses, and nutrition therapy provided by treating doctors will be recorded. Data will be securely stored in a shared electronic database to ensure consistency across multiple hospitals participating in the network. Participants will be infants under 6 months diagnosed with acute malnutrition. Researchers will gather clinical data, anthropometric measurements, feeding details, and lab results during hospital stay. The study will monitor nutritional status changes up to 24 weeks or until discharge and track outcomes such as mortality. Results will help develop evidence-based feeding guidelines and improve clinical care for malnourished infants in Indonesia.

Age: 1Day - 6MonthsAll Genders
16 locations
S

Actively Recruiting

Women who have experienced preeclampsia during pregnancy face a higher risk of heart disease later in life due to lasting damage to blood vessels. This trial evaluates whether a new treatment using mesenchymal stem cell-derived exosomes can help repair blood vessel damage in postpartum women with a history of preeclampsia. Preeclampsia causes high blood pressure and endothelial dysfunction, leading to serious long-term cardiovascular risks. Participants will receive either a single dose of exosome therapy or a placebo through an intravenous or intramuscular injection. The exosomes contain healing substances such as growth factors and microRNAs that may promote blood vessel repair. The study includes 80 women randomly assigned to receive either the treatment or placebo, with follow-up visits extending up to 24 months to monitor long-term effects. Women in the study will undergo blood tests, vital sign checks, and imaging to assess blood vessel function and health. Researchers will measure changes in endothelial function biomarkers, blood pressure, blood counts, and edema at baseline and one week after treatment. Safety and health will be closely monitored throughout the study period, including proteinuria and uterine artery function, to evaluate the treatments impact on vascular repair and cardiovascular risk reduction.

Age: 18Years - 50YearsFEMALEPhase 1Phase 2
1 location

1-10 of 16

1